Getting ivt mrna synthesis right from the template outwards: why the ivt template and its linearisation decide more about the product than the enzyme does, what t7 rna polymerase, t7 in vitro transcription conditions and the in vitro transcription kits built around them control in yield and in double stranded byproduct and where a custom enzyme order (enzyme custom, in a catalogue's phrasing) is worth placing, how mrna ivt capping and tailing choices change potency, what self amplifying rna adds in dose sparing and in construct complexity, when an mrna synthesis kit or a transfection kit off the shelf is enough and when custom mrna from an mrna cdmo is the only route, what gfp mrna, egfp mrna and mrna gfp are useful for as process controls, what an mrna transfection reagent and lipid nanoparticles mrna formulation add to the problem, how large scale mrna production and mrna gmp manufacturing differ from a bench reaction, what mrna reprogramming and talen mrna work demand of purity, and what mrna production release testing and potency testing should report

Building the process

1. Design the template with the product's ends in mind. The transcript begins where the promoter says and ends where the template ends, so linearisation site and completeness of digestion define the three prime end. Incomplete linearisation gives long runoff products that are difficult to remove later. Verify the cut before every transcription rather than trusting a stock preparation.
2. Choose the capping strategy deliberately. Co transcriptional capping with a cap analogue is simpler and gives a defined structure in one step; enzymatic capping after transcription can give higher capping efficiency at the cost of another unit operation. Both are defensible. What is not defensible is being unable to state your capping efficiency.
3. Decide how the tail is added. Encoding the tail in the template gives a defined, reproducible length; enzymatic tailing gives a distribution. Defined length is easier to control and easier to characterise, and it removes an assay you would otherwise have to run on every lot.
4. Control the double stranded byproduct. Transcription generates double stranded species that are potent innate immune activators, and they are the usual explanation for an mRNA that works in a cell free assay and fails in cells. Modified nucleotides reduce the problem; purification that specifically removes double stranded species addresses it directly.
5. Purify against the intended use. Precipitation is adequate for a transfection control. Chromatographic purification is what a potency sensitive application needs, and it is the step that usually separates a research preparation from one that behaves consistently in animals or in people.
6. Write the release panel before the first lot. Identity, integrity, concentration, capping efficiency, tail length, residual template, residual protein and double stranded content, with acceptance criteria agreed in advance. A panel written after a failure is a panel written to explain it.

The template is a process input, not a reagent

Most transcription problems are template problems. Plasmid preparation quality, completeness of linearisation, residual nicked material and the exact sequence at the runoff end all propagate into the product, and none of them are visible in the transcription reaction itself. Treat the linearised template as a controlled intermediate with its own acceptance criteria.

For larger campaigns the template becomes a manufactured item in its own right, with a documented plasmid source, a qualified linearisation and a release check. That is a cost most first plans omit entirely.

Purity is a potency question

For messenger RNA, impurity and potency are the same conversation. Double stranded species, residual template, residual polymerase and incomplete caps all reduce the fraction of the dose that does what the sequence encodes, and some of them actively provoke a response that suppresses translation.

This is why chromatographic purification tends to arrive in a programme at the same moment as the first serious animal study. Planning it in from the start is cheaper than discovering it after an equivocal result.

What to ask a manufacturing partner

Which capping and tailing strategies they run as standard, what double stranded content they routinely achieve and how they measure it, what their release panel contains, and what scale steps exist between the bench and the intended campaign size.

Ask also what stays with you. Template ownership, analytical method transfer and the right to move the process elsewhere are negotiated at the start or not at all.

Common questions

Why does my mRNA work in vitro and not in cells?

The usual cause is double stranded byproduct triggering innate immune sensing, followed by incomplete capping. Both are process problems rather than sequence problems, and both are fixed by purification and capping strategy rather than by redesigning the construct.

Is a kit sufficient for preclinical work?

For process controls and early cell work, often yes. Once potency matters or an animal study depends on the material, the purification and characterisation a kit does not include become the difference between interpretable and uninterpretable results.

Should the tail be encoded or added enzymatically?

Encoded, where the construct allows it. A defined length is reproducible, characterisable and removes a source of lot to lot variation that is otherwise difficult to control.

What changes at manufacturing scale?

Everything about control rather than chemistry. Raw material qualification, a validated linearisation, in process controls, a defined purification train, environmental control and a documented release panel. The reaction is the smallest part of the transfer.

Browse by service class

• Compare Gene synthesis on advertised prices